Falconieri Visuals

Drug Induced Polymerization & Degradation of BCL6 

Prev Next
Previous

Coronavirus SARS CoV 2

medical illustration of Cell Reports Cover, April 2022. Targeted protein degradation is a powerful potential therapeutic approach. Here, cancer-related protein BCL6 is bound by a novel small molecule inhibitor (blue) that causes filament formation and subsequent degradation. Cover art based on: Słabicki M, Yoon H, Koeppel J, et al. Small-molecule-induced polymerization triggers degradation of BCL6. Nature. 2020;588(7836):164-168. doi:10.1038/s41586-020-2925-1 Structures: PDB 6XMX
Next medical illustration of First of an illustration series showing Convergent Therapeutics’ radio-antibody mechanism of action (MoA) in cancer for the Convergent website. Keywords: biotech, radiotherapy, radioantibody, cancer, oncology

Radioantibody structure

Cell Reports Cover, April 2022. Targeted protein degradation is a powerful potential therapeutic approach. Here, cancer-related protein BCL6 is bound by a novel small molecule inhibitor (blue) that causes filament formation and subsequent degradation. Cover art based on: Słabicki M, Yoon H, Koeppel J, et al. Small-molecule-induced polymerization triggers degradation of BCL6. Nature. 2020;588(7836):164-168. doi:10.1038/s41586-020-2925-1 Structures: PDB 6XMX

Keywords: Color, 3D, Models, Advertising / Marketing, Editorial, Publishing, Biology, Biotechnology, Molecular Biology, Mechanism of Action (MOA)

V. Falconieri Hays